(Q33394153)

English

A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). (English)

1 reference

Europe PubMed Central

26 July 2017

phase II clinical trial

0 references

0 references

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

Randy D Gascoyne

4

object named as

Randy D Gascoyne

1 reference

Europe PubMed Central

26 July 2017

author name string

C Tom Kouroukis

1

1 reference

Europe PubMed Central

26 July 2017

Louis A V Fernandez

2

1 reference

Europe PubMed Central

26 July 2017

Michael Crump

3

1 reference

Europe PubMed Central

26 July 2017

Neil Sun Chua

5

1 reference

Europe PubMed Central

26 July 2017

Rena Buckstein

6

1 reference

Europe PubMed Central

26 July 2017

Robert Turner

7

1 reference

Europe PubMed Central

26 July 2017

Sarit Assouline

8

1 reference

Europe PubMed Central

26 July 2017

Richard J Klasa

9

1 reference

Europe PubMed Central

26 July 2017

Wendy Walsh

10

1 reference

Europe PubMed Central

26 July 2017

Jean Powers

11

1 reference

Europe PubMed Central

26 July 2017

Elizabeth Eisenhauer

12

1 reference

Europe PubMed Central

26 July 2017

publication date

1 March 2011

1 reference

Europe PubMed Central

26 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

26 July 2017

52

1 reference

Europe PubMed Central

26 July 2017

3

1 reference

Europe PubMed Central

26 July 2017

394-399

1 reference

Europe PubMed Central

26 July 2017

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Proteasome inhibition as a novel therapeutic target in human cancer.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Gemcitabine for relapsed or resistant lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.546015

21 January 2018

Identifiers

10.3109/10428194.2010.546015

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33394153&oldid=1948190705"